NCT02300987View on ClinicalTrials.gov

A Randomized, Blinded, Placebo-controlled, Phase II Trial of LEE011 in Patients With Relapsed, Refractory, Incurable Teratoma With Recent Progression

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 26, 2015

Primary Completion Date

February 21, 2018

Study Completion Date

February 21, 2018

Conditions
Teratoma
Interventions
DRUG

LEE011

DRUG

LEE011 Placebo

Trial Locations (7)

10017

Memorial Sloan Kettering Oncology Department., New York

28041

Novartis Investigative Site, Madrid

87106

New Mexico Cancer Care Alliance, Albuquerque

90033

USC Kenneth Norris Comprehensive Cancer Center Oncology Dept, Los Angeles

94800

Novartis Investigative Site, Villejuif

9713 GZ

Novartis Investigative Site, Groningen

08907

Novartis Investigative Site, L'Hospitalet de Llobregat

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY